123 related articles for article (PubMed ID: 10470430)
21. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Valcárcel D; Sanz G; Ortega M; Nomdedeu B; Luño E; Diez-Campelo M; Ardanaz MT; Pedro C; Montoro J; Collado R; Andreu R; Marco V; Cedena MT; de Paz R; Tormo M; Xicoy B; Ramos F; Bargay J; Gonzalez B; Brunet S; Muñoz JA; Gomez V; Bailén A; Sanchez J; Merchán B; del Cañizo C; Vallespí T;
Lancet Haematol; 2015 Jun; 2(6):e260-6. PubMed ID: 26688236
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
[TBL] [Abstract][Full Text] [Related]
23. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
24. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.
Benton CB; Khan M; Sallman D; Nazha A; Nogueras González GM; Piao J; Ning J; Aung F; Al Ali N; Jabbour E; Kadia TM; Borthakur G; Ravandi F; Pierce S; Steensma D; DeZern A; Roboz G; Sekeres M; Andreeff M; Kantarjian H; Komrokji RS; Garcia-Manero G
Am J Hematol; 2018 Oct; 93(10):1245-1253. PubMed ID: 30051599
[TBL] [Abstract][Full Text] [Related]
26. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
28. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Kantarjian H; O'Brien S; Ravandi F; Cortes J; Shan J; Bennett JM; List A; Fenaux P; Sanz G; Issa JP; Freireich EJ; Garcia-Manero G
Cancer; 2008 Sep; 113(6):1351-61. PubMed ID: 18618511
[TBL] [Abstract][Full Text] [Related]
29. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the prognosis of patients with myelodysplastic syndromes.
Aul C; Giagounidis A; Germing U; Ganser A
Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348
[TBL] [Abstract][Full Text] [Related]
31. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
32. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
[TBL] [Abstract][Full Text] [Related]
33. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems.
Rubio-Felix D; Giraldo P; Franco E; Gimeno J; Giralt M
Hematol Oncol; 1995; 13(3):139-52. PubMed ID: 7622144
[TBL] [Abstract][Full Text] [Related]
35. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
[TBL] [Abstract][Full Text] [Related]
36. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes.
Savic A; Marisavljevic D; Kvrgic V; Stanisavljevic N
Acta Haematol; 2014; 131(4):231-8. PubMed ID: 24335346
[TBL] [Abstract][Full Text] [Related]
38. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
39. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
[TBL] [Abstract][Full Text] [Related]
40. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
